Non-financial Assets and Liabilities (Details) - USD ($) |
12 Months Ended | ||
|---|---|---|---|
Jun. 30, 2026 |
Jun. 30, 2025 |
Jun. 30, 2024 |
|
| Non-financial Assets and Liabilities [Line Items] | |||
| Provisions (in Dollars) | $ 697,907 | $ 450,104 | $ 399,788 |
| Accrued leave or require payment | 12 months | ||
| AVb6 Integrin [Member] | |||
| Non-financial Assets and Liabilities [Line Items] | |||
| Probability directors’ assumptions | 70.00% | ||
| Amortized over a period | 20 years | ||
| hu PSA Anti-body [Member] | |||
| Non-financial Assets and Liabilities [Line Items] | |||
| Probability directors’ assumptions | 70.00% | ||
| Amortized over a period | 15 years | ||
| NanoMab [Member] | |||
| Non-financial Assets and Liabilities [Line Items] | |||
| Probability directors’ assumptions | 70.00% | ||
| Amortized over a period | 20 years | ||
| Pivalate [Member] | |||
| Non-financial Assets and Liabilities [Line Items] | |||
| Amortized over a period | 15 years | ||
| MAb [Member] | |||
| Non-financial Assets and Liabilities [Line Items] | |||
| Amortized over a period | 20 years |